The FDA cleared RHA Dynamic Volume for midface augmentation and age-related volume loss, broadening Revance's dynamic-filler portfolio beyond the original RHA Collection indication for facial lines. Dynamic fillers — which retain movement and adapt to facial expression — have gained clinical traction as practitioners move away from overfilled, static results. RHA's mechanism (reverse crosslinking) is distinct from traditional HA fillers and appeals to patients seeking natural-looking correction.
Injectables
FDA Clears RHA Dynamic Volume for Midface Augmentation — Revance's Dynamic Filler Gains Broader Indication
Revance's RHA line now covers midface volume loss; the approval expands the dynamic-filler category beyond facial lines.
RHA Dynamic Volume now covers midface augmentation, expanding Revance's dynamic-filler footprint.
The midface indication is strategically important because midface volume loss is a primary driver of aging and a high-value treatment zone. Practices already using RHA for lines can now upsell midface augmentation to the same patient cohort, increasing per-patient revenue. However, Revance's market penetration remains smaller than Allergan or Galderma; practices on Allē or Aspire loyalty programs may face friction in switching loyalty or stocking a third major filler line. The approval signals Revance's commitment to competing on indication breadth, but adoption will depend on rebate competitiveness and practitioner education.
Source: original report ↗
Frequently asked questions
What is RHA Dynamic Volume and how is it different from other dermal fillers?
RHA Dynamic Volume uses reverse crosslinking technology, which allows the filler to retain facial movement and adapt to expressions—unlike traditional static HA fillers that can look overfilled. This mechanism makes it particularly suited for patients seeking natural-looking results rather than frozen or heavily augmented appearances.
What is the new FDA approval for RHA Dynamic Volume?
The FDA cleared RHA Dynamic Volume for midface augmentation and age-related volume loss, expanding Revance's indication beyond the original RHA Collection approval for facial lines. This approval allows practitioners to treat midface volume loss, a primary driver of facial aging, in a high-value treatment zone.
Why is midface volume loss treatment important for med spas?
Midface volume loss is a primary driver of aging and represents a high-value treatment zone. Practices already using RHA for lines can now upsell midface augmentation to existing patients, increasing per-patient revenue and treatment scope.
Will RHA Dynamic Volume compete with Allergan and Galderma fillers?
Revance's market penetration remains smaller than Allergan or Galderma, and practices on loyalty programs like Allē or Aspire may face friction switching to a third major filler line. Adoption will depend on rebate competitiveness and practitioner education about RHA's dynamic properties and clinical benefits.
What are dynamic fillers and why are practitioners using them more?
Dynamic fillers retain movement and adapt to facial expression, contrasting with traditional static fillers that can appear frozen or overfilled. Practitioners are increasingly adopting them as patient demand shifts away from overfilled results toward more natural-looking facial correction.
Free weekly brief
Get the free weekly brief.
The week's most important moves in medical aesthetics — distilled to a two-minute read, free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief every morning. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.